

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Buch-Rasmussen et al.
Serial No. : 09/550,857 Examiner: Fonda, K.
Filed : April 17, 2000 Art Unit: 1623
Title : Dry, Mouldable Drug Formulation

RECEIVED
FEB 05 2002
TECH CENTER 1600/2800
#11 MW

I hereby certify that this paper is being deposited with the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on December 6, 2001.

Robert B. Smith

Reg. No. 28,538

Robert B. Smith
Signature

December 6, 2001
Date

December 6, 2001

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor is this Information Disclosure Statement a representation that a search has been made.


Enclosures accompanying this Information Disclosure Statement are:

- (1) Form PTO-1449;
- (2) Copies of publications.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the latter of three months after the U.S. Patent application filing date or the first Office Action on the merits. Accordingly, no fee or certification is required.

The Commissioner is authorized to charge any additional fee required or credit any overpayment for the Information Disclosure Statement to Skadden, Arps, Slate, Meagher & Flom LLP Deposit Account No. 19-2385.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Robert B. Smith", written over a horizontal line.

Robert B. Smith

PTO Registration No. 28,538

Attorney for applicant(s)

(212) 735-3020

Skadden, Arps, Slate, Meagher & Flom
Four Times Square
New York, NY 20036-6522